More about
Apolipoprotein C-Iii
News
June 03, 2024
3 min read
Save
Plozasiran lowers APOC3, triglycerides, other lipids in high-risk populations
In patients with severe hypertriglyceridemia, plozasiran, a novel RNA interference agent, lowered apolipoprotein C-III and triglycerides and improved other lipid parameters, according to the final results of the phase 2b SHASTA-2 trial.